Literature DB >> 27182625

Time to Diagnostic Evaluation After Mammographic Screening in an Urban Setting.

Bridget A Oppong1,2, Chiranjeev Dash2, Tesha Coleman3, Tanya Torres3, Lucile L Adams-Campbell2.   

Abstract

BACKGROUND: The Capital Breast Care Center (CBCC), a screening facility established to serve minority women, developed a culturally sensitive patient care paradigm that would address concerns of adherence to follow-up of abnormal results after initial mammogram. Women with abnormal mammograms are assigned a Black or Latina navigator who facilitates the additional workup needed by scheduling follow-up, arranging transportation, providing counsel/emotional support, and even accompanying them to diagnostic imaging or biopsy appointment. We present data on follow-up rates after breast cancer screening.
METHODS: All patients seen at CBCC are entered into a prospectively collected database. We calculated intervals (in days) between the screening and diagnostic visits. Descriptive statistics and median time to follow-up are reported. Differences between Black and Hispanic women on time interval were tested by t-test.
RESULTS: From January 2010 to December 2012, 4605 digital screening mammograms were performed. Fifty-two percent of the women self-identified as Black, 41% as Hispanic, 4% White, 2% Asian, and 1% as "other." Of the screening studies, 451 (9.8%) required additional workup, out of which 362 (80%) of the women returned for the recommended diagnostic imaging. The median interval between screening and diagnostic imaging was 39 days (range: 6-400). Of the 162 women recommended to have a core needle biopsy, 81.5% underwent biopsy within a median of 21 days (range: 0-221 days).
CONCLUSION: At the CBCC, time to patient follow-up after initial mammographic screening is within the CDC-recommended performance standard of less than 60 days. For a population that historically has low rates of clinical follow-up, we attribute this reduction in delays to breast cancer diagnostic resolution to a culturally sensitive patient navigation program. Additional studies are needed to assess how the existing navigation program can be individualized/tailored to target the remaining 20% of women who did not adhere to the recommended workup.

Entities:  

Keywords:  breast cancer; diagnostic; minority health; patient navigation; screening mammography

Mesh:

Year:  2016        PMID: 27182625      PMCID: PMC6453486          DOI: 10.1089/jwh.2015.5661

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  5 in total

1.  Improving Breast Cancer Outcomes Through Patient Navigation.

Authors:  Lisa C Richardson
Journal:  J Womens Health (Larchmt)       Date:  2016-11-21       Impact factor: 2.681

2.  A Community-Based Outreach Navigator Approach to Establishing Partnerships for a Safety Net Mammography Screening Center.

Authors:  Sherrie Wallington; Bridget Oppong; Chiranjeev Dash; Tesha Coleman; Holly Greenwald; Tanya Torres; Marquita Iddirisu; Lucile Lauren Adams-Campbell
Journal:  J Cancer Educ       Date:  2018-08       Impact factor: 2.037

3.  Breast density in multiethnic women presenting for screening mammography.

Authors:  Bridget A Oppong; Chiranjeev Dash; Suzanne O'Neill; Yinan Li; Kepher Makambi; Edward Pien; Erini Makariou; Tesha Coleman; Lucile L Adams-Campbell
Journal:  Breast J       Date:  2017-10-24       Impact factor: 2.431

4.  Time to diagnostic resolution after an uncertain screening mammogram in an underserved population.

Authors:  Anita J Kumar; Darcy Banco; Elise E Steinberger; Joanna Chen; RuthAnn Weidner; Shital Makim; Susan K Parsons
Journal:  Cancer Med       Date:  2020-03-11       Impact factor: 4.452

5.  Real-world challenges for patients with breast cancer in sub-Saharan Africa: a retrospective observational study of access to care in Ghana, Kenya and Nigeria.

Authors:  Majid Twahir; Razaq Oyesegun; Joel Yarney; Andrew Gachii; Clement Edusa; Chukwumere Nwogu; Gitangu Mangutha; Philip Anderson; Emmanuel Benjamin; Borna Müller; Charles Ngoh
Journal:  BMJ Open       Date:  2021-03-02       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.